Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.

@article{Gargiulo2016ImpactOP,
  title={Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.},
  author={Giuseppe Gargiulo and Francesco Vittorio Costa and Sara Ariotti and Simone Biscaglia and Gianluca Campo and Giovanni Esposito and Sergio Leonardi and Pascal Vranckx and Stephan Windecker and Marco Valgimigli},
  journal={American heart journal},
  year={2016},
  volume={174},
  pages={95-102}
}
BACKGROUND Proton pump inhibitors (PPIs) are frequently prescribed in combination with clopidogrel, but conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We assessed the association between PPI use and clinical outcomes for patients treated with percutaneous coronary intervention (PCI) and dual-antiplatelet therapy (DAPT) with… CONTINUE READING